Yamanouchi Pharmaceutical Co., Ltd., and Fujisawa Pharmaceutical Co., Ltd., merged to form a new corporation named Astellas Pharma, Inc.
Yamanouchi Pharmaceutical Co., Ltd., and Fujisawa Pharmaceutical Co., Ltd., merged to form a new corporation named Astellas Pharma, Inc. The company said its focus will be on developing breakthrough products in various areas, including urology. The company will continue to support such drugs as solifenacin succinate (Vesicare) for the treatment of overactive bladder, tamsulosin hydrochloride (Flomax) for the treatment of BPH, and tacrolimus (Prograf) for the prevention of the treatment of organ rejection after liver and kidney transplants.
